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**On page 247, the following tables should have appeared as follows:**

###### 

Summary of effects of pharmacological agents on bone mineral density and fracture risk according to randomized, controlled trials.

  Agent(s)                      BMD   Hip fractures   Vertebral fractures   Other Fractures
  ----------------------------- ----- --------------- --------------------- -----------------
  Alendronate/risedronate       ↑     ↓               ↓                     ↓
  Calcitonin                    ↑     N/D             ↓                     N/D
  Calcitriol                    ↑     N/D             ↓                     ↓
  Calcium                       ↑     N/D             ↓                     N/D
  Hormone replacement therapy   ↑     ↓               ↓                     ↓
  Raloxifene                    ↑     N/D             ↓                     N/D

N/D: Not demonstrated (No effect demonstrated, or evidence is not conclusive).

###### 

Recommendations for treatment of osteoporosis.

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  BMD with T score above −1, or a FRACTURE Index score with BMD of \<6 -- Calcium and vitamin D-- Exercise and other lifestyle changes-- Consider follow--up BMD assessment in 5 years, if indicatedBMD with T score −1 to −2.5 -- Calcium and vitamin D-- If there is history of fracture(s), or \>1 strong risk factor for fractures, or a FRACTURE Index score with BMD 6, consider treatment with a bisphosphonate, SERM, HRT, or calcitonin, as appropriate.-- Consider a follow-up BMD assessment in 2 years, particularly if patient is not receiving pharmacological therapyBMD with T score below −2.5 -- Calcium and vitamin D-- If there is a history of fracture(s), or 1 strong risk factor for fractures, or a FRACTURE Index score with BMD 6, treat with a bisphosphonate, SERM, HRT, or calcitonin, as appropriate-- Consider a follow-up BMD assessment in 1--2 years
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Article in full: <http://app.kfshrc.edu.sa/annals/Articles/24_4/03-175.pdf>
